Den 17 december 2020 hölls bolagstämma i Ortoma AB. Vid stämman fattades följande beslut:
Pressmeddelandet som skickades ut idag den 17 december klockan 12:04 innehöll av misstag MAR-etikett.
Val av revisor
Mazars valdes som bolagets revisionsbolag. Mazars har utsett David Johansson som huvudansvarig revisor.
Göteborg den 17 december 2020
Ortoma AB
Styrelsen
About Ortoma AB (publ)
Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company’s surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the patient. Ortoma’s surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries – and thus better long-term survival rates for implants. OTS is a system that is easily integrated into the processes and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. In Sweden, around 42,000 surgical procedures were performed last year, involving hip, knee or spinal surgery. Ortoma’s B shares are listed on Spotlight Stock Market.